MOLN
Molecular Partners AG Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website molecularpartners.com
- Employees(FY) 175
- ISIN US60853G1067
Performance
-4.52%
1W
-3.8%
1M
-15.65%
3M
-8.38%
6M
-9.09%
YTD
-42.6%
1Y
Profile
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; as well as other third-party collaborators. It also has a collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Technical Analysis of MOLN 2024-05-10
Overview:
In analyzing the technical indicators for MOLN stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible future stock price movement. By examining these key indicators, we aim to offer valuable insights and recommendations for potential inves...
Recent News & Updates
- 2024-04-28 23:00
- 2024-04-18 23:12
Life Science Cares Launches in Switzerland(Globenewswire)
- 2024-04-16 23:12
- 2024-03-25 21:26
- 2024-03-14 04:00
- 2024-03-01 03:00
- 2024-01-07 03:00
- 2024-01-05 03:00
- 2023-12-13 12:00
- 2023-12-09 23:00
- 2023-11-13 12:00
- 2023-11-03 00:00
- 2023-11-01 14:00
- 2023-10-31 14:00
- 2023-10-26 04:00
- 2023-09-12 13:00
- 2023-08-24 04:00
- 2023-07-12 20:06
- 2023-06-26 13:00
- 2023-06-19 00:00
- 2023-06-01 20:59
- 2023-05-25 05:01
- 2023-05-16 04:00
- 2023-05-12 14:00
- 2023-05-11 04:00
- 2023-04-17 13:44
- 2023-04-13 13:00
- 2023-04-03 23:44
- 2023-03-12 21:30
- 2023-03-12 12:22
Page 1 of 4
previousnext